

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Hypertension	CXC chemokine receptor 2 (CXCR2; IL8RB)	<p><i>In vitro</i> and mouse studies suggest CXCR2 antagonists could help treat familial pulmonary arterial hypertension (PAH). In a mouse model of PAH, the CXCR2 antagonist SCH527123 decreased both leukocyte infiltration in the lungs and pulmonary vascular remodeling and increased cardiac output compared with vehicle. Future studies could include testing CXCR2 antagonists in animal models of nonfamilial PAH.</p> <p>Navarixin (SCH527123) from Ligand Pharmaceuticals Inc. and Merck & Co. Inc. is in Phase II testing to treat chronic obstructive pulmonary disease (COPD).</p> <p>SB-656933, a CXCR2 antagonist from GlaxoSmithKline plc, is in Phase II testing to treat cystic fibrosis (CF).</p> <p>AZD5069, a CXCR2 antagonist from AstraZeneca plc, is in Phase II testing to treat COPD.</p> <p>SciBX 4(37); doi:10.1038/scibx.2011.1041 Published online Sept. 22, 2011</p>	Patent and licensing status unavailable	<p>Burton, V.J. <i>et al. Blood</i>; published online Sept. 7, 2011; doi:10.1182/blood-2011-05-347393</p> <p>Contact: Victoria J. Burton, Novartis Institutes for BioMedical Research, Horsham, U.K. e-mail: victoria.burton@novartis.com</p>